Does the enlargement of a cavitation beneath the inferior alveolar nerve on a 2024 CBCT, indicating communication with the mandibular canal, alter the etiology and recommended treatment plan?

Growing Mandibular Cavitation with Inferior Alveolar Nerve Involvement: Diagnostic and Treatment Implications

The enlargement of a cavitation below the inferior alveolar nerve (IAN) with mandibular canal communication fundamentally changes both the diagnostic approach and treatment strategy—this is no longer a simple periodontal or endodontic lesion, but rather demands immediate consideration of neurogenic tumors (schwannoma, neurofibroma), medication-related osteonecrosis of the jaw (MRONJ), or aggressive odontogenic pathology requiring surgical intervention with nerve preservation planning.

Critical Diagnostic Shift

The progressive growth pattern you describe—specifically the cavitation continuing below and enlarging around the IAN—is a red flag that distinguishes this from benign static lesions. The key differentiating features are:

Neurogenic Tumor Consideration (Primary Concern)

Intraosseous schwannoma must be at the top of your differential diagnosis given the specific anatomical relationship. These tumors characteristically:

• Cause inferior displacement of the mandibular canal and mental foramen enlargement/remodeling 1
• Present with radiographic-clinical dissociation—meaning dramatic radiographic changes despite preserved neurosensory function 1
• Show progressive growth over time
• Appear as well-defined radiolucencies that can mimic odontogenic lesions 1

The 2026 case report emphasizes that absence of neurosensory symptoms does NOT exclude neurogenic origin 1. The patient in that study had completely normal mental nerve function despite marked canal displacement and foramen enlargement—exactly matching your clinical scenario.

MRONJ Stage Assessment

If the patient has any history of bisphosphonate or denosumab use (even oral bisphosphonates for osteoporosis), this changes everything. According to the 2019 MASCC/ISOO/ASCO guidelines 2:

• Stage 3 MRONJ is defined by exposed/necrotic bone with "osteolysis extending to the inferior border of the mandible" 2
• Treatment requires surgical debridement or resection for long-term palliation 2
• The growing nature and IAN involvement would classify this as advanced disease requiring aggressive management

Aggressive Odontogenic Pathology

The 2025 literature on mandibular canal displacement 3 identifies eight primary entities that displace the canal:

• Ameloblastoma (most aggressive, requires resection)
• Odontogenic keratocyst (high recurrence, requires enucleation with peripheral ostectomy)
• Dentigerous cyst (if associated with impacted tooth) 4
• Central giant cell granuloma
• Aneurysmal bone cyst

The progressive enlargement pattern strongly suggests ameloblastoma or keratocyst over simple cyst.

Mandatory Immediate Workup

Before any treatment decision:

1. High-resolution small field-of-view CBCT (if not already done optimally) to:

   • Assess three-dimensional root-neural topography 4
   • Identify cortical perforation, inferior border involvement
   • Measure exact relationship to IAN canal 5
   • Look for mental foramen remodeling/enlargement 1

2. Incisional biopsy is non-negotiable before definitive treatment:

   • The 2026 schwannoma case emphasizes that radiographic diagnosis alone is insufficient 1
   • Histopathology with S100 protein and neuron-specific enolase staining differentiates schwannoma 1
   • If MRONJ, will show necrotic bone without viable osteocytes 2

3. Detailed medication history:

   • Any bisphosphonate use (even years prior—long half-life) 2
   • Denosumab (shorter half-life, may benefit from temporary discontinuation) 2
   • Antiangiogenic agents 2

Treatment Algorithm Based on Etiology

If Schwannoma (or Neurogenic Tumor):

Surgical excision with nerve preservation is the definitive treatment 1:

• En bloc resection of the encapsulated mass
• Expect intraoperative finding of tumor adherent to IAN near mental foramen 1
• Anticipate mild postoperative hypoesthesia (typically resolves within 5 months) 1
• Piezoelectric ultrasonic instrumentation minimizes neural trauma 4
• Postoperative protocol: Methylprednisolone 4mg daily × 3 days + Mecobalamin 0.5mg TID for neural recovery 4

If MRONJ Stage 3:

Following 2019 MASCC/ISOO/ASCO guidelines 2:

• Surgical debridement or resection (not conservative management)
• Oral antibiotics + topical antibacterial rinse
• Pain control
• Communication with oncologist mandatory before BMA discontinuation 2
• Denosumab discontinuation may enhance resolution (weigh against skeletal-related event risk) 2
• 8-week follow-up intervals 2

If Ameloblastoma/Aggressive Odontogenic Lesion:

• Segmental resection with margins (ameloblastoma)
• Enucleation with peripheral ostectomy (keratocyst)
• IAN sacrifice may be necessary depending on tumor involvement
• Reconstruction planning (bone graft, plate fixation)

Critical Pitfalls to Avoid

1. Do NOT attempt conservative endodontic or periodontal treatment if this is neurogenic or MRONJ—you will delay definitive care and risk progression

2. Do NOT assume benign cyst based on well-defined borders—schwannomas mimic odontogenic lesions radiographically 1

3. Do NOT rely on presence/absence of paresthesia for diagnosis—neurogenic tumors can be completely asymptomatic 1

4. Do NOT extract teeth or perform invasive procedures before biopsy if MRONJ is suspected—this can precipitate acute worsening 2

5. Ensure independent CBCT interpretation—the 2025 case report 6 highlights how misinterpretation of initial CBCT delayed proper referral and worsened outcomes

Immediate Action Plan

Refer to oral and maxillofacial surgeon immediately for:

• Incisional biopsy under local anesthesia
• Definitive surgical planning based on histopathology
• Nerve preservation strategy if schwannoma confirmed
• Resection planning if ameloblastoma/MRONJ

The progressive growth pattern is the game-changer—static lesions can sometimes be observed, but documented enlargement with IAN involvement demands tissue diagnosis and likely surgical intervention regardless of final etiology.